Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2
{ "count": 24333, "next": "http://api.gregory-ms.com/articles/?format=api&page=3", "previous": "http://api.gregory-ms.com/articles/?format=api", "results": [ { "article_id": 283126, "title": "Comparison of macular changes according to the etiology of optic neuritis: a cross-sectional study", "summary": "<jats:p>AIM: To compare the macular structure including foveal thickness among patients with optic neuritis (ON) according to the etiology and to investigate the possible correlation between structural and visual outcomes\nMETHODS: In this retrospective cross-sectional study, the clinical data of patients with aquaporin-4 immunoglobulin G-related ON (AQP4 group, 40 eyes), myelin oligodendrocyte glycoprotein IgG-related ON (MOG group, 31 eyes), and multiple sclerosis-related ON (MS group, 24 eyes) were obtained. The retinal thickness of the foveal, parafoveal and perifoveal regions were measured. Visual acuity (VA), visual field index and mean deviation were measured as visual outcomes.\nRESULTS: The AQP4 group showed a significantly thinner fovea (226.4±13.4 μm) relative to the MOG (236.8±14.0 μm, P=0.015) and MS (238.9±14.3 μm, P=0.007) groups. The thickness in the parafoveal area also was thinner in the AQP4 group, though the difference in perifoveal retinal thickness was not significant. Foveal thickness was correlated with VA in the AQP4 group (coefficient ρ=-0.418, P=0.014), but not in the MOG and MS groups (P=0.218 and P=0.138, respectively). There was no significant correlation between foveal thickness and visual field test in all three groups.\nCONCLUSION: The significant thinning in the fovea and parafoveal areas in the AQP4 group compared to the MOG and MS groups are found. Additionally, macular changes in AQP4-ON show a significant correlation with VA. The results provide the possibility that retinal structural damage could reflect functional damage in AQP4-ON, distinct from MOG-ON and MS-ON.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38638247/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-19T10:00:00Z", "source": "PubMed", "publisher": "Press of International Journal of Ophthalmology (IJO Press)", "container_title": "International Journal of Ophthalmology", "authors": [ { "author_id": 323601, "given_name": "Yeji", "family_name": "Moon", "ORCID": "http://orcid.org/0000-0002-9553-2231", "country": null }, { "author_id": 193644, "given_name": "Jae Ho", "family_name": "Jung", "ORCID": "http://orcid.org/0000-0003-4742-4903", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T11:25:42.550278Z", "noun_phrases": null, "doi": "10.18240/ijo.2024.04.12", "access": "open", "takeaways": "AQP4 group showed a significantly thinner fovea and parafoveal retinal thickness than MOG and MS groups. There was no correlation between foveal thickness and visual field test in all three groups.", "categories": [] }, { "article_id": 283125, "title": "Robotic systems for upper-limb rehabilitation in multiple sclerosis: a SWOT analysis and the synergies with virtual and augmented environments", "summary": "<jats:p>The robotics discipline is exploring precise and versatile solutions for upper-limb rehabilitation in Multiple Sclerosis (MS). People with MS can greatly benefit from robotic systems to help combat the complexities of this disease, which can impair the ability to perform activities of daily living (ADLs). In order to present the potential and the limitations of smart mechatronic devices in the mentioned clinical domain, this review is structured to propose a concise SWOT (Strengths, Weaknesses, Opportunities, and Threats) Analysis of robotic rehabilitation in MS. Through the SWOT Analysis, a method mostly adopted in business management, this paper addresses both internal and external factors that can promote or hinder the adoption of upper-limb rehabilitation robots in MS. Subsequently, it discusses how the synergy with another category of interaction technologies - the systems underlying virtual and augmented environments - may empower Strengths, overcome Weaknesses, expand Opportunities, and handle Threats in rehabilitation robotics for MS. The impactful adaptability of these digital settings (extensively used in rehabilitation for MS, even to approach ADL-like tasks in safe simulated contexts) is the main reason for presenting this approach to face the critical issues of the aforementioned SWOT Analysis. This methodological proposal aims at paving the way for devising further synergistic strategies based on the integration of medical robotic devices with other promising technologies to help upper-limb functional recovery in MS.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38638271/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-19T10:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Robotics and AI", "authors": [ { "author_id": 348546, "given_name": "Giulia A.", "family_name": "Albanese", "ORCID": null, "country": null }, { "author_id": 348547, "given_name": "Anna", "family_name": "Bucchieri", "ORCID": null, "country": null }, { "author_id": 158732, "given_name": "Jessica", "family_name": "Podda", "ORCID": "http://orcid.org/0000-0002-9327-9148", "country": null }, { "author_id": 150295, "given_name": "Andrea", "family_name": "Tacchino", "ORCID": "http://orcid.org/0000-0002-2263-7315", "country": null }, { "author_id": 348548, "given_name": "Stefano", "family_name": "Buccelli", "ORCID": null, "country": null }, { "author_id": 348549, "given_name": "Elena", "family_name": "De Momi", "ORCID": null, "country": null }, { "author_id": 348550, "given_name": "Matteo", "family_name": "Laffranchi", "ORCID": null, "country": null }, { "author_id": 299627, "given_name": "Kailynn", "family_name": "Mannella", "ORCID": null, "country": null }, { "author_id": 299629, "given_name": "Michael W. R.", "family_name": "Holmes", "ORCID": null, "country": null }, { "author_id": 348551, "given_name": "Jacopo", "family_name": "Zenzeri", "ORCID": null, "country": null }, { "author_id": 323975, "given_name": "Lorenzo", "family_name": "De Michieli", "ORCID": null, "country": null }, { "author_id": 147769, "given_name": "Giampaolo", "family_name": "Brichetto", "ORCID": "http://orcid.org/0000-0003-2026-3572", "country": null }, { "author_id": 348552, "given_name": "Giacinto", "family_name": "Barresi", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T11:25:40.901935Z", "noun_phrases": null, "doi": "10.3389/frobt.2024.1335147", "access": "open", "takeaways": "People with MS can greatly benefit from robotic systems to help combat the complexities of this disease. This review presents SWOT Analysis of robotic rehabilitation in MS.", "categories": [] }, { "article_id": 283124, "title": "Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale", "summary": "<jats:p> A multicenter study involving 204 adults with relapsing-remitting multiple sclerosis (RRMS) assessed the dimensionality and item characteristics of the Mishel-Uncertainty of Illness Scale (MUIS), a generic self-assessment tool. Mokken analysis identified two dimensions in the MUIS with an appropriate item and overall scale scalability after excluding nonclassifiable items. A refined 12-item MUIS, employing a grade response model, effectively discriminated uncertainty levels among RRMS patients (likelihood ratio test p-value = .03). These findings suggest the potential value of the 12-item MUIS as a reliable measure for assessing uncertainty associated with the course of illness in RRMS. </jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38638273/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-19T10:00:00Z", "source": "PubMed", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal - Experimental, Translational and Clinical", "authors": [ { "author_id": 268667, "given_name": "Julia", "family_name": "Sabin", "ORCID": null, "country": null }, { "author_id": 285935, "given_name": "Elisa", "family_name": "Salas", "ORCID": null, "country": null }, { "author_id": 257343, "given_name": "Jesús", "family_name": "Martín-Martínez", "ORCID": null, "country": null }, { "author_id": 348537, "given_name": "Antonio", "family_name": "Candeliere-Merlicco", "ORCID": "http://orcid.org/0000-0001-9978-0198", "country": null }, { "author_id": 348538, "given_name": "Francisco Javier", "family_name": "Barrero", "ORCID": null, "country": null }, { "author_id": 230423, "given_name": "Ana", "family_name": "Alonso", "ORCID": "http://orcid.org/0000-0002-7337-8384", "country": null }, { "author_id": 258362, "given_name": "José Luis", "family_name": "Sánchez-Menoyo", "ORCID": null, "country": null }, { "author_id": 253442, "given_name": "Laura", "family_name": "Borrega", "ORCID": null, "country": null }, { "author_id": 348539, "given_name": "María", "family_name": "Rodríguez-Rodríguez", "ORCID": null, "country": null }, { "author_id": 348540, "given_name": "Montserrat", "family_name": "Gómez-Gutiérrez", "ORCID": null, "country": null }, { "author_id": 160157, "given_name": "Sara", "family_name": "Eichau", "ORCID": "http://orcid.org/0000-0001-9159-3128", "country": null }, { "author_id": 348541, "given_name": "Miguel Ángel", "family_name": "Hernández-Pérez", "ORCID": null, "country": null }, { "author_id": 253443, "given_name": "Carmen", "family_name": "Calles", "ORCID": null, "country": null }, { "author_id": 328453, "given_name": "Eva", "family_name": "Fernández-Díaz", "ORCID": null, "country": null }, { "author_id": 193280, "given_name": "Olga", "family_name": "Carmona", "ORCID": "http://orcid.org/0000-0002-5957-0046", "country": null }, { "author_id": 348542, "given_name": "Aida", "family_name": "Orvíz", "ORCID": null, "country": null }, { "author_id": 348543, "given_name": "Ana", "family_name": "López-Real", "ORCID": null, "country": null }, { "author_id": 348544, "given_name": "Pablo", "family_name": "López-Muñoz", "ORCID": null, "country": null }, { "author_id": 348545, "given_name": "Amelia", "family_name": "Mendoza", "ORCID": null, "country": null }, { "author_id": 202928, "given_name": "Eduardo", "family_name": "Agüera", "ORCID": "http://orcid.org/0000-0002-8604-2054", "country": null }, { "author_id": 148143, "given_name": "Jorge", "family_name": "Maurino", "ORCID": "http://orcid.org/0000-0001-9858-3555", "country": null }, { "author_id": 252241, "given_name": "Javier", "family_name": "Ballesteros", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T11:25:38.946436Z", "noun_phrases": null, "doi": "10.1177/20552173241247680", "access": "open", "takeaways": "A multicenter study involving 204 adults with relapsing-remitting multiple sclerosis (RRMS) assessed the Mishel-Uncertainty of Illness Scale (MUIS), a generic self-assessment", "categories": [] }, { "article_id": 283123, "title": "Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy", "summary": "<jats:p>Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce relapse frequency, magnetic resonance imaging (MRI) activity, and slow disability progression. Numerous DMTs are approved for relapsing forms of MS although real-world data on patient-reported outcomes (PROs) and quality of life (QoL) are needed to inform treatment choice. Immune reconstitution therapy with cladribine tablets is a highly effective treatment for relapsing MS (RMS). We present the protocol for an observational study to prospectively assess the effectiveness of cladribine tablets on clinical and MRI parameters as well as on PROs, including treatment satisfaction, QoL, sleep quality, self-perceived health, fatigue, and physical function. Enrolled patients at study sites in Italy will be adults with RMS (including relapsing–remitting and active secondary progressive MS) who are either treatment naïve or have received at least one first-line disease modifying DMT or no more than one second-line DMT. The primary objective will be change in global treatment satisfaction measured with the Treatment Satisfaction Questionnaire for Medication Version 1.4 approximately 24 months after initiating cladribine tablets in patients switching from previous DMTs. Secondary objectives will include global treatment satisfaction at earlier timepoints, will comprise treatment naïve patients, and will quantify treatment effectiveness and tolerability. We will also assess relapses, disability progression, MRI activity, and other PROs at approximately 12 and 24 months. The findings will provide insight from daily clinical practice into the patient’s experience to complement data from controlled trials and inform treatment choice. EU PAS Registration Number EUPAS49334 filed 17/10/2022.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38638312/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-19T10:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Neurology", "authors": [ { "author_id": 143061, "given_name": "Massimo", "family_name": "Filippi", "ORCID": "http://orcid.org/0000-0002-5485-0479", "country": null }, { "author_id": 328261, "given_name": "Laura", "family_name": "Ferrè", "ORCID": "http://orcid.org/0000-0002-0559-5301", "country": null }, { "author_id": 328260, "given_name": "Chiara", "family_name": "Zanetta", "ORCID": "http://orcid.org/0000-0001-6372-360X", "country": null }, { "author_id": 303918, "given_name": "Caterina", "family_name": "Rizzi", "ORCID": null, "country": null }, { "author_id": 348536, "given_name": "Gabriella", "family_name": "Pessina", "ORCID": null, "country": null }, { "author_id": 272495, "given_name": "Francesco", "family_name": "Assogna", "ORCID": null, "country": null }, { "author_id": 236921, "given_name": "Maria A.", "family_name": "Rocca", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T11:25:37.610250Z", "noun_phrases": null, "doi": "10.3389/fneur.2024.1379712", "access": "open", "takeaways": "Immune reconstitution therapy with cladribine tablets is a highly effective treatment for relapsing MS (RMS). We present the protocol for an observational study to prospectively assess the effectiveness of the treatment. The primary objective will be change in global treatment satisfaction measured with the Treatment Satisfaction Questionnaire for Medication Version 1.4 approximately 24 months after the start of treatment. Secondary objectives will include global treatment dissatisfaction at earlier timepoints and quantify treatment effectiveness and tolerability", "categories": [] }, { "article_id": 283122, "title": "The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study", "summary": "Gut microbiota has complex immune functions, related to different pathologies, including multiple sclerosis (MS).This study evaluated the influence of treatments on gut microbiota in people with MS (PwMS). The research comprised 60 participants, including 39 PwMS and 21 healthy controls (HC). Among the PwMS, 20 were prescribed a disease-modifying therapy (DMT), either interferon beta1a or teriflunomide, while 19 received a combination of classical DMT and an immunoglobulin Y (IgY) supplement....", "link": "https://pubmed.ncbi.nlm.nih.gov/38638559/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-19T10:00:00Z", "source": "PubMed", "publisher": null, "container_title": null, "authors": [], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T11:25:36.645027Z", "noun_phrases": null, "doi": "10.15698/mic2024.03.819", "access": "restricted", "takeaways": "Gut microbiota has complex immune functions related to different pathologies, including MS. Study evaluated the influence of treatments on gut microbiota in people with MS.", "categories": [] }, { "article_id": 283121, "title": "A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis", "summary": "<jats:p> Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of MS pathogenesis, along with mast cells, establishing the relevance of BTK inhibitors to diverse autoimmune conditions. First-generation BTK inhibitors are currently utilized in the treatment of B-cell malignancies and show efficacy in B-cell modulation. B-cell depleting therapies have shown success as disease-modifying treatments (DMTs) in MS, highlighting the potential of BTK inhibitors for this indication; however, first-generation BTK inhibitors exhibit a challenging safety profile that is unsuitable for chronic use, as required for MS DMTs. A second generation of highly selective BTK inhibitors has shown efficacy in modulating MS-relevant mechanisms of pathogenesis in preclinical as well as clinical studies. Six of these BTK inhibitors are undergoing clinical development for MS, three of which are also under investigation for chronic spontaneous urticaria (CSU), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Phase II trials of selected BTK inhibitors for MS showed reductions in new gadolinium-enhancing lesions on magnetic resonance imaging scans; however, the safety profile is yet to be ascertained in chronic use. Understanding of the safety profile is developing by combining safety insights from the ongoing phase II and III trials of second-generation BTK inhibitors for MS, CSU, RA and SLE. This narrative review investigates the potential of BTK inhibitors as an MS DMT, the improved selectivity of second-generation inhibitors, comparative safety insights established thus far through clinical development programmes and proposed implications in female reproductive health and in long-term administration. </jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38638671/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-19T10:00:00Z", "source": "PubMed", "publisher": "SAGE Publications", "container_title": "Therapeutic Advances in Neurological Disorders", "authors": [ { "author_id": 241608, "given_name": "Laura", "family_name": "Airas", "ORCID": null, "country": null }, { "author_id": 150024, "given_name": "Robert A.", "family_name": "Bermel", "ORCID": "http://orcid.org/0000-0003-2334-6883", "country": null }, { "author_id": 143340, "given_name": "Tanuja", "family_name": "Chitnis", "ORCID": "http://orcid.org/0000-0002-9897-4422", "country": null }, { "author_id": 181330, "given_name": "Hans-Peter", "family_name": "Hartung", "ORCID": "http://orcid.org/0000-0002-0614-6989", "country": null }, { "author_id": 250306, "given_name": "Jin", "family_name": "Nakahara", "ORCID": null, "country": null }, { "author_id": 147499, "given_name": "Olaf", "family_name": "Stuve", "ORCID": "http://orcid.org/0000-0002-0469-6872", "country": null }, { "author_id": 341858, "given_name": "Mitzi J.", "family_name": "Williams", "ORCID": "http://orcid.org/0000-0001-6979-1101", "country": "US" }, { "author_id": 273447, "given_name": "Bernd C.", "family_name": "Kieseier", "ORCID": null, "country": null }, { "author_id": 160394, "given_name": "Heinz", "family_name": "Wiendl", "ORCID": "http://orcid.org/0000-0003-4310-3432", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T11:25:35.409345Z", "noun_phrases": null, "doi": "10.1177/17562864241233041", "access": "open", "takeaways": "Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of MS. First-generation BTK inhibitors are currently utilized in the treatment of B-cell malignancies. Second-generation inhibitors have shown efficacy in modulating MS-relevant mechanisms of pathogenesis. Six of them are in clinical development for MS", "categories": [] }, { "article_id": 283118, "title": "Frequency of an intrathecal IgM synthesis and MRZ reaction in children with MS", "summary": "CONCLUSION: An intrathecal IgM synthesis and a positive MRZR are found in a subset of MS children but are not associated with markers associated with a poor prognosis.", "link": "https://pubmed.ncbi.nlm.nih.gov/38636242/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-18T10:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "European Journal of Paediatric Neurology", "authors": [ { "author_id": 348525, "given_name": "Bertolini", "family_name": "A", "ORCID": null, "country": null }, { "author_id": 348526, "given_name": "G.", "family_name": "Koukou", "ORCID": null, "country": null }, { "author_id": 348527, "given_name": "E.M.", "family_name": "Wendel", "ORCID": null, "country": null }, { "author_id": 252669, "given_name": "C.", "family_name": "Thiels", "ORCID": null, "country": null }, { "author_id": 164653, "given_name": "Matthias", "family_name": "Baumann", "ORCID": "http://orcid.org/0000-0003-4471-8324", "country": null }, { "author_id": 188690, "given_name": "Christian", "family_name": "Lechner", "ORCID": "http://orcid.org/0000-0002-2720-1019", "country": null }, { "author_id": 348528, "given_name": "A.", "family_name": "Blaschek", "ORCID": null, "country": null }, { "author_id": 348529, "given_name": "A.", "family_name": "Della Marina", "ORCID": "http://orcid.org/0000-0003-0737-6142", "country": null }, { "author_id": 348530, "given_name": "G.", "family_name": "Classen", "ORCID": null, "country": null }, { "author_id": 348531, "given_name": "B.", "family_name": "Stüve", "ORCID": null, "country": null }, { "author_id": 348532, "given_name": "B.", "family_name": "Kauffmann", "ORCID": null, "country": null }, { "author_id": 348533, "given_name": "T.", "family_name": "Kapanci", "ORCID": null, "country": null }, { "author_id": 348534, "given_name": "B.", "family_name": "Mayer", "ORCID": "http://orcid.org/0000-0003-1042-9006", "country": null }, { "author_id": 155458, "given_name": "Markus", "family_name": "Otto", "ORCID": "http://orcid.org/0000-0003-4273-4267", "country": null }, { "author_id": 348535, "given_name": "K.", "family_name": "Rostásy", "ORCID": null, "country": null }, { "author_id": 348524, "given_name": "S.", "family_name": "Chen", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T05:25:36.709220Z", "noun_phrases": null, "doi": "10.1016/j.ejpn.2024.04.005", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283117, "title": "Diet and omega-3 and vitamin D supplement use predict five-year fatigue and disability trajectories in people with multiple sclerosis", "summary": "CONCLUSIONS: A high-quality diet, avoiding meat and dairy, and omega-3 and vitamin D supplement use, individually predict better fatigue and disability trajectories. Dietary modifications should be considered in MS management.", "link": "https://pubmed.ncbi.nlm.nih.gov/38636270/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-18T10:00:00Z", "source": "PubMed", "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 235471, "given_name": "Xin", "family_name": "Lin", "ORCID": "http://orcid.org/0000-0002-1563-8168", "country": null }, { "author_id": 173263, "given_name": "Amin", "family_name": "Zarghami", "ORCID": "http://orcid.org/0000-0002-1135-0255", "country": "AU" }, { "author_id": 296956, "given_name": "George A", "family_name": "Jelinek", "ORCID": null, "country": null }, { "author_id": 151806, "given_name": "Steve", "family_name": "Simpson-Yap", "ORCID": "http://orcid.org/0000-0001-6521-3056", "country": null }, { "author_id": 258139, "given_name": "Sandra", "family_name": "Neate", "ORCID": null, "country": null }, { "author_id": 158394, "given_name": "N", "family_name": "Nag", "ORCID": "http://orcid.org/0000-0002-0271-0781", "country": "AU" } ], "relevant": true, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T05:25:35.556411Z", "noun_phrases": null, "doi": "10.1016/j.msard.2024.105615", "access": "open", "takeaways": "", "categories": [] }, { "article_id": 283116, "title": "Variability in the prevalence of depression among adults with chronic pain: UK Biobank analysis through clinical prediction models", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n<jats:title>Background</jats:title>\n<jats:p>The prevalence of depression among people with chronic pain remains unclear due to the heterogeneity of study samples and definitions of depression. We aimed to identify sources of variation in the prevalence of depression among people with chronic pain and generate clinical prediction models to estimate the probability of depression among individuals with chronic pain.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Methods</jats:title>\n<jats:p>Participants were from the UK Biobank. The primary outcome was a “lifetime” history of depression. The model’s performance was evaluated using discrimination (optimism-corrected C statistic) and calibration (calibration plot).</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Results</jats:title>\n<jats:p>Analyses included 24,405 patients with chronic pain (mean age 64.1 years). Among participants with chronic widespread pain, the prevalence of having a “lifetime” history of depression was 45.7% and varied (25.0–66.7%) depending on patient characteristics. The final clinical prediction model (optimism-corrected C statistic: 0.66; good calibration on the calibration plot) included age, BMI, smoking status, physical activity, socioeconomic status, gender, history of asthma, history of heart failure, and history of peripheral artery disease. Among participants with chronic regional pain, the prevalence of having a “lifetime” history of depression was 30.2% and varied (21.4–70.6%) depending on patient characteristics. The final clinical prediction model (optimism-corrected C statistic: 0.65; good calibration on the calibration plot) included age, gender, nature of pain, smoking status, regular opioid use, history of asthma, pain location that bothers you most, and BMI.</jats:p>\n</jats:sec><jats:sec>\n<jats:title>Conclusions</jats:title>\n<jats:p>There was substantial variability in the prevalence of depression among patients with chronic pain. Clinically relevant factors were selected to develop prediction models. Clinicians can use these models to assess patients’ treatment needs. These predictors are convenient to collect during daily practice, making it easy for busy clinicians to use them.</jats:p>\n</jats:sec>", "link": "https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03388-x", "published_date": "2024-04-18T23:00:00Z", "source": "BioMedCentral", "publisher": "Springer Science and Business Media LLC", "container_title": "BMC Medicine", "authors": [ { "author_id": 348511, "given_name": "Lingxiao", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 348512, "given_name": "Claire E", "family_name": "Ashton-James", "ORCID": null, "country": null }, { "author_id": 348513, "given_name": "Baoyi", "family_name": "Shi", "ORCID": null, "country": null }, { "author_id": 348514, "given_name": "Maja R", "family_name": "Radojčić", "ORCID": null, "country": null }, { "author_id": 348515, "given_name": "David B", "family_name": "Anderson", "ORCID": null, "country": null }, { "author_id": 348463, "given_name": "Yujie", "family_name": "Chen", "ORCID": "http://orcid.org/0000-0002-9905-9138", "country": "CN" }, { "author_id": 348516, "given_name": "David B", "family_name": "Preen", "ORCID": null, "country": null }, { "author_id": 348517, "given_name": "John L", "family_name": "Hopper", "ORCID": null, "country": null }, { "author_id": 245152, "given_name": "Shuai", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 348518, "given_name": "Minh", "family_name": "Bui", "ORCID": null, "country": null }, { "author_id": 348519, "given_name": "Paula R", "family_name": "Beckenkamp", "ORCID": null, "country": null }, { "author_id": 348520, "given_name": "Nigel K", "family_name": "Arden", "ORCID": null, "country": null }, { "author_id": 348521, "given_name": "Paulo H", "family_name": "Ferreira", "ORCID": null, "country": null }, { "author_id": 348522, "given_name": "Hengxing", "family_name": "Zhou", "ORCID": null, "country": null }, { "author_id": 264753, "given_name": "Shiqing", "family_name": "Feng", "ORCID": null, "country": null }, { "author_id": 348523, "given_name": "Manuela L", "family_name": "Ferreira", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-19T04:26:48.873160Z", "noun_phrases": null, "doi": "10.1186/s12916-024-03388-x", "access": "open", "takeaways": "There is substantial variability in the prevalence of depression among patients with chronic pain. Clinically relevant factors were selected to develop prediction models. Clinicians can use these models to assess patients’ treatment needs.", "categories": [] }, { "article_id": 283114, "title": "Generation and characterization of monoclonal antibodies against pathologically phosphorylated TDP-43", "summary": "<jats:p>Inclusions containing TAR DNA binding protein 43 (TDP-43) are a pathological hallmark of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). One of the disease-specific features of TDP-43 inclusions is the aberrant phosphorylation of TDP-43 at serines 409/410 (pS409/410). Here, we developed rabbit monoclonal antibodies (mAbs) that specifically detect pS409/410-TDP-43 in multiple model systems and FTD/ALS patient samples. Specifically, we identified three mAbs (26H10, 2E9 and 23A1) from spleen B cell clones that exhibit high specificity and sensitivity to pS409/410-TDP-43 peptides in an ELISA assay. Biochemical analyses revealed that pS409/410 of recombinant TDP-43 and of exogenous 25 kDa TDP-43 C-terminal fragments in cultured HEK293T cells are detected by all three mAbs. Moreover, the mAbs detect pS409/410-positive TDP-43 inclusions in the brains of FTD/ALS patients and mouse models of TDP-43 proteinopathy by immunohistochemistry. Our findings indicate that these mAbs are a valuable resource for investigating TDP-43 pathology both <jats:italic>in vitro</jats:italic> and <jats:italic>in vivo</jats:italic>.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38635657/?fc=20210216052009&ff=20240419182534&v=2.18.0.post9+e462414", "published_date": "2024-04-18T10:00:00Z", "source": "PubMed", "publisher": "Public Library of Science (PLoS)", "container_title": "PLOS ONE", "authors": [ { "author_id": 348482, "given_name": "Paula", "family_name": "Castellanos Otero", "ORCID": null, "country": null }, { "author_id": 348483, "given_name": "Tiffany W.", "family_name": "Todd", "ORCID": null, "country": null }, { "author_id": 340624, "given_name": "Wei", "family_name": "Shao", "ORCID": null, "country": null }, { "author_id": 348484, "given_name": "Caroline J.", "family_name": "Jones", "ORCID": null, "country": null }, { "author_id": 348485, "given_name": "Kexin", "family_name": "Huang", "ORCID": null, "country": null }, { "author_id": 348486, "given_name": "Lillian M.", "family_name": "Daughrity", "ORCID": null, "country": null }, { "author_id": 294643, "given_name": "Mei", "family_name": "Yue", "ORCID": null, "country": null }, { "author_id": 348487, "given_name": "Udit", "family_name": "Sheth", "ORCID": "http://orcid.org/0000-0003-4360-7892", "country": null }, { "author_id": 323435, "given_name": "Tania F.", "family_name": "Gendron", "ORCID": "http://orcid.org/0000-0002-7335-2627", "country": null }, { "author_id": 218904, "given_name": "Mercedes", "family_name": "Prudencio", "ORCID": "http://orcid.org/0000-0002-4894-4858", "country": "US" }, { "author_id": 249356, "given_name": "Björn", "family_name": "Oskarsson", "ORCID": null, "country": null }, { "author_id": 233222, "given_name": "Dennis W.", "family_name": "Dickson", "ORCID": "http://orcid.org/0000-0001-7189-7917", "country": "US" }, { "author_id": 332481, "given_name": "Leonard", "family_name": "Petrucelli", "ORCID": "http://orcid.org/0000-0003-2959-129X", "country": null }, { "author_id": 348488, "given_name": "Yong-Jie", "family_name": "Zhang", "ORCID": "http://orcid.org/0000-0002-9900-4313", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-04-18T23:25:34.351613Z", "noun_phrases": null, "doi": "10.1371/journal.pone.0298080", "access": "restricted", "takeaways": "Inclusions containing TAR DNA binding protein 43 (TDP-43) are a pathological hallmark of frontotemporal dementia (FTD) and", "categories": [] } ] }